Intabio (SCIEX)

Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing. The development and manufacturing of biologics requires high levels of monitoring and testing due to the fact that antibody and recombinant protein drugs are produced in living cells that often introduce unintended structural modifications that can affect efficacy and toxicity. Current testing systems are cumbersome and do not provide the throughput and real-time protein analytics that today’s rapidly growing biopharma industry desperately needs. Constrained by time and resources, and faced with thousands of samples requiring analysis, samples are cherry-picked or pooled for characterization. This strategy leads to incomplete knowledge of the product quality, and potential costly missteps and delays during development. Intabio was founded to address the critical issue in protein analytics and our solution is based on a decade’s worth of deep customer insight. We are developing the Blaze system (bench-top instrument, microfluidic chip, reagent kit) to address the acute pain in biologic product development and manufacturing by providing real-time, rapid, and direct characterization of intact protein isoforms in a simple and easy to use system. Blaze uses a proprietary microfluidic platform to separate and quantitate protein isoforms based on charge heterogeneity, and if an unknown protein peak is identified, Blaze can directly interface with a mass spectrometer (MS) to identify the specific modification. Our proprietary technology provides the unique integration of three analytical techniques for separation, quantitation, and molecular mass identity that are widely used today across development, regulatory approval, and commercial manufacturing.